Skip to main content

Fees and funding

Article-processing charges

Open access publishing is not without costs. Genome Medicine therefore levies an article-processing charge of £2990.00/$4290.00/€3490.00 for each article accepted for publication, plus VAT or local taxes where applicable.

If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.

BMC provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.

For more information on APCs please see our Journal Pricing FAQs

  • Editorial Board
  • Editorial Team
  • Sign up for article alerts and news from this journal
  • Contact us
  • Announcements

    C19 Rapid Review initiative

    Genome Medicine has joined the C19 Rapid Review initiative, a cross-publisher collaboration to ensure that COVID-19 research is reviewed and published as quickly and openly as possible. Learn more here

    Submissions from medRxiv 

    Authors are now able to submit manuscripts to Genome Medicine directly from medRxiv without having to re-upload files.

    Portable peer review

    To reduce time spent on serial submissions and iterative reviewing, Genome Medicine offers to consider manuscripts on the basis of reviews received at other journals. We also support transfers of reviews obtained at Genome Medicine to other journals, including those outside of BMC and Springer Nature. Learn more from our peer review policy page.

    COVID-19 submissions

    In response to the current SARS-CoV-2 pandemic Genome Medicine editors will treat relevant submissions with high priority.